Intal Nebulizer Solution

Name: Intal Nebulizer Solution

Side effects

Clinical experience with the use of INTAL suggests that adverse reactions are rare events. The following adverse reactions have been associated with INTAL

Nebulizer Solution: cough, nasal congestion, nausea, sneezing, and wheezing.

Other reactions have been reported in clinical trials; however, a causal relationship could not be established: drowsiness, nasal itching, nose bleed, nose burning, serum sickness, and stomachache.

In addition, adverse reactions have been reported with INTAL Capsules (cromolyn sodium for inhalation, USP). The most common side effects are associated with inhalation of the powder and include transient cough (1 in 5 patients) and mild wheezing (1 in 25 patients). These effects rarely require treatment or discontinuation of the drug.

Information on the incidence of adverse reactions to INTAL Capsules has been derived from U.S. postmarketing surveillance experience. The following adverse reactions attributed to INTAL, based upon recurrence following readministration, have been reported in less than 1 in 10,000 patients: laryngeal edema, swollen parotid gland, angioedema, bronchospasm, joint swelling and pain, dizziness, dysuria and urinary frequency, nausea, cough, wheezing, headache, nasal congestion, rash, urticaria, and lacrimation.

Other adverse reactions have been reported in less than 1 in 100,000 patients, and it is unclear whether these are attributable to the drug: anaphylaxis, nephrosis, periarteritic vasculitis, pericarditis, peripheral neuritis, pulmonary infiltrates with eosinophilia, polymyositis, exfoliative dermatitis, hemoptysis, anemia, myalgia, hoarseness, photodermatitis, and vertigo.

Read the entire FDA prescribing information for Intal Nebulizer Solution (Cromolyn Sodium Inhalation Solution)

Read More »

Warnings

Intal has no role in the treatment of status asthmaticus.

Anaphylactic reactions with cromolyn sodium administration have been reported rarely.

How Supplied

Intal Nebulizer Solution is a colorless solution supplied in a low density polyethylene plastic unit dose ampule with 12 ampules per foil pouch. Each 2 mL ampule contains 20 mg cromolyn sodium, USP, in purified water.

NDC 60793-010-60...................60 ampules x 2 mL

NDC 60793-010-12..................120 ampules x 2 mL

Store at Controlled Room Temperature 20° to 25°C (68° to 77°F) [see USP]. Protect from light. Do not use if it contains a precipitate or becomes discolored. Keep out of the reach of children.

Store ampules in foil pouch until ready for use.

Intal® is a registered trademark King Pharmaceuticals, Inc.

Prescribing Information as of September 2005

Distributed by: King Pharmaceuticals, Inc. Bristol, TN 37620

Manufactured by: Cardinal Health Woodstock, IL 60098 USA

Intal NEBULIZER 
cromolyn sodium inhalant
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:60793-010
Route of Administration RESPIRATORY (INHALATION) DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
cromolyn sodium (cromolyn) cromolyn 20 mg  in 2 mL
Packaging
# Item Code Package Description
1 NDC:60793-010-60 60 AMPULE (60 AMPULE) in 1 POUCH
1 2 mL (2 MILLILITER) in 1 AMPULE
2 NDC:60793-010-12 120 AMPULE (120 AMPULE) in 1 POUCH
2 2 mL (2 MILLILITER) in 1 AMPULE
Labeler - King Pharmaceuticals, Inc.
Revised: 10/2006   King Pharmaceuticals, Inc.
(web3)